Physician profile
Nathan Quaderer
NPI 1760971451
$2,620.13
in general payments reported to CMS, 2019-2025
33 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $209 · 2021: $228 · 2022: $302 · 2023: $450 · 2024: $355 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $347.46 | 2024-2025 | |
| Novo Nordisk INC | $331.39 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $294.39 | 2019-2021 | |
| Lilly USA, LLC | $256.43 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $212.97 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $182.18 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $145.58 | 2022-2023 | Xywav |
| Neurocrine Biosciences, INC. | $102.08 | 2021 | |
| Gilead Sciences, INC. | $79.63 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $77.08 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $73.42 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $47.07 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $42.71 | 2022 | |
| Exact Sciences Corporation | $41.61 | 2025 | Cologuard Collection Kit |
| Cranial Technologies, INC | $32.66 | 2025 | Doc Band |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $30.62 | 2025 | Fanapt |
| Globus Medical, INC. | $26.04 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.70 | 2022 | |
| Collegium Pharmaceutical, INC. | $24.57 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.01 | 2024 | Jardiance |
| Impel Pharmaceuticals INC. | $22.87 | 2022 | |
| Glaxosmithkline, LLC. | $20.01 | 2024 | Trelegy Ellipta |
| Photonicare INC | $19.35 | 2025 | Otosight Middle Ear Scope |
| Indivior INC. | $18.85 | 2024 | Sublocade |
| Alnylam Pharmaceuticals INC. | $18.55 | 2023 | Onpattro |
| Merck Sharp & Dohme LLC | $18.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.88 | 2022 | |
| Mylan Specialty L.P. | $17.60 | 2022 | |
| Abbott Laboratories | $16.58 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.64 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.26 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.72 | 2019 | |
| Amarin Pharma, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Quaderer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.